Price T Rowe Associates Inc Macrogenics Inc Transaction History

Price T Rowe Associates Inc

$867 Billion
Q4 2024

A detailed history of Price T Rowe Associates Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 485,987 shares of MGNX stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

485,987

Previous 1,254,236 61.25%

Holding current value

$1.2 Million

Previous $4.13 Million 61.69%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$3.18 - $4.46 $2.44 Million - $3.43 Million	-768,249 Reduced 61.25%	485,987 $1.58 Million
Q3 2024 Nov 14, 2024	SELL	$3.0 - $5.55 $248,352 - $459,451	-82,784 Reduced 6.19%	1,254,236 $4.13 Million
Q2 2024 Aug 14, 2024	SELL	$3.31 - $18.51 $3.64 Million - $20.4 Million	-1,101,030 Reduced 45.16%	1,337,020 $5.68 Million
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $23.5 Million - $51.7 Million	2,409,237 Added 8361.63%	2,438,050 $35.9 Million
Q4 2023 Feb 14, 2024	SELL	$4.48 - $10.11 $18,807 - $42,441	-4,198 Reduced 12.72%	28,813 $278,000
Q3 2023 Nov 14, 2023	BUY	$4.48 - $6.19 $35,992 - $49,730	8,034 Added 32.17%	33,011 $154,000
Q2 2023 Aug 14, 2023	BUY	$4.62 - $7.54 $1,081 - $1,764	234 Added 0.95%	24,977 $134,000
Q1 2023 May 15, 2023	BUY	$4.82 - $7.24 $4,704 - $7,066	976 Added 4.11%	24,743 $178,000
Q4 2022 Feb 14, 2023	BUY	$3.34 - $6.98 $18,744 - $39,171	5,612 Added 30.91%	23,767 $159,000
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $20,567 - $35,668	-6,833 Reduced 27.35%	18,155 $63,000
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $675 - $2,997	300 Added 1.22%	24,988 $74,000
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $11,538 - $24,014	1,421 Added 6.11%	24,688 $218,000
Q4 2021 Feb 14, 2022	SELL	$15.91 - $21.88 $225,922 - $310,696	-14,200 Reduced 37.9%	23,267 $373,000
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $86,856 - $126,280	4,400 Added 13.31%	37,467 $785,000
Q2 2021 Aug 16, 2021	SELL	$20.49 - $35.63 $450 - $783	-22 Reduced 0.07%	33,067 $888,000
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $69,826 - $122,076	3,677 Added 12.5%	33,089 $1.05 Million
Q4 2020 Feb 16, 2021	BUY	$19.41 - $26.0 $570,886 - $764,712	29,412 New	29,412 $672,000

Others Institutions Holding MGNX

# of Institutions

131

Shares Held

56M

Call Options Held

28.3K

Put Options Held

197K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $151M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Macrogenics Inc Transaction History